安炎达医药技术

Anyanda is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the development of next-generation small molecule drugs for autoimmune and inflammatory disorders. The company's core expertise lies in structure-based drug design and medicinal chemistry, which it applies to create highly selective kinase inhibitors. Its lead candidate, AYD-001, is a potent and selective TYK2 inhibitor currently undergoing clinical evaluation for the treatment of psoriasis and other immune-mediated conditions. Anyanda aims to provide oral therapeutic alternatives that offer improved safety and efficacy profiles compared to existing biologics and systemic treatments. The firm is supported by leading venture capital investors, including Qiming Venture Partners and TF Capital.